title: Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease.
abstract: OBJECTIVE
  Ileocolonoscopy including biopsies is the first-line investigation in the diagnosis, management, and monitoring of inflammatory bowel disease (IBD). However, data on its safety, feasibility, and tolerability, especially in patients with extensive or severe inflammation, are rare. The aim of this study was to assess prospectively the risks of ileocolonoscopy in relation to various disease patterns and to compare possible burdens of the procedure in the endoscopist's and the patient's perception.
  
  
  METHODS
  We prospectively analyzed a total of 558 consecutive patients, 482 with a confirmed diagnosis of IBD and 76 with suspected IBD. Data were recorded regarding the indication for ileocolonoscopy, sedation, procedure time, completion rate, feasibility of the procedure, patient tolerance, and procedure-related and postprocedure complications. Endoscopic data included the region involved, the nature of the involvement, activity of the disease, and number of biopsies.
  
  
  RESULTS
  In 558 endoscopic procedures performed by 14 gastroenterologists no procedure-related deaths occurred. Major complications, defined as bleeding (n = 1) or perforation (n = 3), occurred in 4/558 patients (0.7 %). Minor complications, which included intense flatulence, tachycardia, allergic reaction to a sedation drug, and autonomic symptoms such as nausea, vomiting, and intense perspiration, occurred in 22/558 patients (3.9 %). There was no relationship between the complication rate and the activity of the disease. Mean procedure time was 21.0 minutes and the completion rate, defined by intubation of the terminal ileum, was 94.6 %. We documented a high tolerability independent of the severity of the disease.
  
  
  CONCLUSIONS
  Ileocolonoscopy is a safe and feasible procedure in patients with IBD and is well tolerated by patients when carried out by well-trained endoscopists.
authors.affiliation: Department of Internal Medicine, Evangelisches Krankenhaus Kalk, Köln, Germany. gterheggen@web.de
authors.forename: G
authors.initials: G
authors.lastname: Terheggen
authors.forename: B
authors.initials: B
authors.lastname: Lanyi
authors.forename: S
authors.initials: S
authors.lastname: Schanz
authors.forename: R M
authors.initials: RM
authors.lastname: Hoffmann
authors.forename: S K
authors.initials: SK
authors.lastname: Böhm
authors.forename: L
authors.initials: L
authors.lastname: Leifeld
authors.forename: C
authors.initials: C
authors.lastname: Pohl
authors.forename: W
authors.initials: W
authors.lastname: Kruis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D016009:Chi-Square Distribution; D003113:Colonoscopy / Q000009:adverse effects / Q000379:methods*; D003937:Diagnosis, Differential; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007082:Ileum / Q000473:pathology; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D012449:Safety; D018709:Statistics, Nonparametric